The National Coalition for Cancer Survivorship was awarded a grant from the American Institutes for Research, with support from the Robert Wood Johnson Foundation, to develop a new quality measure concept for “return to functional status.”
Richard Pazdur, FDA’s top oncologist who last week received a battlefield promotion to the role of director of the FDA Center for Drug Evaluation and Research, is described as a stabilizing figure respected by major patient groups, oncology professional societies, and the industry.
